Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIR-ICG MRL for Lymphatic Transport
NCT04046146Phase 1Completed
- Sponsor
- University of Rochester
- Start
- Dec 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of indocyanine green in rheumatoid arthritis (RA) and lymphedema, sponsored by University of Rochester. Primary endpoints: Manual lymphatic vessel counts via assessment of 2D images of NIR-ICG compared to MRI at 12 months, Lymphatic contraction rate measured via NIR ICG camera at 12 months and 1 more. Started Dec 2019; status: completed.
02
Drugs
indocyanine green
03
Conditions
rheumatoid arthritis (RA)lymphedema
Beyond the preview
Go deeper on NCT04046146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04046146.